Robert J. Hugin – Chief Executive Officer of Celgene Corporation – Email Address

Robert J. Hugin ("Bob") is the CEO of Celgene Corporation, a biopharmaceutical company with operations in more than 50 countries.[1]

Mr. Hugin became the CEO of Celgene Corporation in June 2010 after already serving as their president and COO from May 2006. He was elected chairman in June 2011 by the Celgene Board of Directors. He first came to Celgene in June 1999 as a senior vice president and CFO and he was elected to their Board of Directors in December 2001.[1] From 1985 until April 1999, Mr. Hugin worked with J.P. Morgan Co. Inc. and was a Managing Director.[2]

In April 2013, Mr. Hugin became the chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). He is also the Independent Director at The Medicines Co. and a Director at Choose New Jersey.[2] He is on many Board of Directors including: The Medicines Co., Atlantic Health System, Inc., Darden School Foundation, Princeton University, Family Promise and the University of Virginia Darden School of Business.[3] He was the Chairman of the HealthCare Institute of New Jersey. He also served as a United States Marine Corps infantry officer.[2]

Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).

Comments are closed.